Neteera
Last updated: May 6, 2026
Neteera develops FDA-cleared, ultra-wideband radar-based contactless vital signs monitoring for healthcare settings, with significant dual-use applicability in security and defense contexts.
Visit WebsiteCompany Overview
Neteera's core technology is a proprietary ultra-wideband (UWB) radar micro-Doppler sensing system that continuously monitors vital signs—heart rate, respiratory rate, oxygen saturation indicators, movement patterns, and sleep metrics—without physical contact, wearables, cameras, or patient cooperation. The system operates through clothing and bedding, using ambient radar signals to detect subtle physiological micro-movements. Real-time signal processing algorithms extract vital signs with clinical-grade accuracy and integrate directly into hospital information systems and electronic health records, generating customized alerts when measurements deviate from baseline or cross predefined thresholds.
The company is headquartered in Jerusalem, Israel, with an operational presence in Lewes, Delaware, reflecting its dual-market strategy. Founded in 2015 by Israeli researchers in sensor physics and healthcare, Neteera has progressed from early-stage R&D through clinical validation to full FDA clearance and CE certification (Medical Device Directive, Notified Body 2797). The platform addresses a critical operational gap in healthcare: continuous monitoring without staff burden, patient disruption, or compliance dependency. In skilled nursing facilities (SNFs), acute care hospitals, and assisted living environments, the system identifies patient deterioration an average of 5 days earlier than conventional vital sign monitoring, directly reducing hospital readmissions and enabling earlier intervention.
Neteera's market entry strategy prioritizes value-based care models, ACOs, and large healthcare systems under pressure to reduce readmissions and improve quality metrics. The contactless modality is particularly valuable in elderly care and post-operative monitoring, where wearable non-compliance and environmental disruption are common barriers to continuous monitoring. The technology eliminates false alarms associated with manual vital sign checks and reduces caregiver workload in understaffed facilities.
The dual-use potential is substantive and credible. The same radar architecture that detects physiological stress signals in hospital beds can be deployed in security screening contexts—borders, checkpoints, secure facilities—to identify individuals under acute physiological stress without physical search. Military field medical applications are also relevant: contactless vital sign monitoring of wounded or unconscious personnel in austere or contaminated environments, enabling medics to rapidly triage casualty severity without removing equipment or approaching directly. These defense applications represent meaningful asymmetry relative to competing vital-sign modalities, which typically require direct contact or wearables.
Dual-Use Assessment
Neteera's radar-based sensing technology has clear dual-use applicability: primary healthcare market monitors vital signs in hospitals and care facilities; secondary defense/security applications include physiological stress detection at borders and checkpoints, and casualty triage support in austere military field medical environments. The contactless architecture provides asymmetric advantage over wired or wearable vital-sign modalities in contested environments.
Strategic Fit Assessment
Priority signal means this entry may be worth researching within the Claw & Talon thesis. It does not mean investable, suitable, endorsed, available, or likely to produce returns.
Neteera represents a compelling dual-use medtech investment: the company has achieved FDA clearance and CE certification for a genuinely differentiated contactless vital signs platform with strong commercial tailwinds (post-pandemic nursing facility staffing crises, value-based care adoption, readmission penalties). The healthcare market alone is substantial and defensible; the secondary defense/security applications represent meaningful optionality. The team has executed a disciplined product-market fit strategy, and the technology is sufficiently novel that sustained competitive moats appear plausible. Series A stage with mature funding pathway and clear commercialization metrics. Risk profile appropriate for portfolio diversification in dual-use deep tech.
Strategic Value to U.S.-Israel Alliance
Neteera's radar-based sensing architecture establishes allied technical competency in contactless vital signs measurement, a critical capability gap in both healthcare resilience (pandemic surge capacity, staffing robustness) and security/defense operations (unobtrusive physiological assessment, field medicine, biometric screening). The Israeli origin and strong technical foundation suggest deeper engagement with allied R&D ecosystems. The technology scales horizontally across multiple security and medical contexts, creating strategic leverage.
Key Technologies
- Ultra-wideband (UWB) micro-Doppler radar sensing
- Physiological signal extraction algorithms (heart rate, respiration, oxygen saturation)
- Real-time clinical alert and workflow integration
- Through-clothing and through-bedding radar propagation
- Continuous passive patient monitoring without wearables or patient compliance
- FDA-cleared contactless vital signs measurement platform
Use Cases & Applications
- Hospital patient deterioration early warning and readmission prevention
- Skilled nursing facility and assisted living continuous monitoring
- Post-operative patient monitoring in acute care
- Elderly care fall risk and pressure injury prevention
- Border and checkpoint physiological stress screening
- Military field medical triage and casualty vital signs assessment
- Sleep analysis and respiratory disorder detection
- Remote patient monitoring in value-based care models
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- Official website Primary public reference for company identity, positioning, and current web presence.
- Profile update timestamp Last updated in the Claw & Talon database on May 6, 2026.
Investor Lens
What this entry is
Private startup
Why it may matter
Neteera may matter as a Semiconductors & DeepTech Hardware entry with direct private-company diligence for Israeli technology research.
How an independent investor should read this
Direct private-company diligence. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify traction
- Verify cap table/funding
- Verify technical claims
- Verify regulatory/export-control issues
- Verify customer concentration
Main investor questions
- Is the company currently active, independently financeable, and raising or not raising on terms you can verify?
- What customer, revenue, product, and technical evidence supports the company story?
- What valuation, cap table, rights, and follow-on assumptions would govern any private exposure?
- Does the dual-use claim map to actual commercial and government/defense/resilience buyer evidence?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Neteera's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Where does the product create real defense, intelligence, critical-infrastructure, or emergency-response value beyond ordinary commercial adoption?
- What export-control, supply-chain, manufacturing, or classified-market constraints could affect U.S. and allied adoption?
- What would disconfirm the priority signal: weak customer references, thin technical differentiation, poor capital efficiency, or limited allied-market access?
Related sector
See the Semiconductors & DeepTech Hardware sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.